Stocks:
5,168
ETFs:
2,288
Exchanges:
11
Market Cap:
$63.92T
24h Vol:
$4.36B
Dominance:
MSFT:4.92%
Stocklytics Platform
Instrument logo  MRKR
Marker Therapeutics Inc
MRKR
81 / 100
High Growth
Penny Stock
$4.53arrow_drop_down1.52%-$0.07

Performance History

Stocklytics logo
Key Stats
Open$4.62
Prev. Close$4.60
EPS-2.86
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap43111748.00
PE Ratio-
LOWHIGH
Day Range4.52
4.62
52 Week Range0.76
9.68
Ratios
P/B Ratio2.94
Revenue$3.31M
Operating M. %-278.06%
Earnings$0.00
Earnings Growth %53.07%
EBITDA Margin %-356.14%
ROE %-83.47%
EPS-2.86

Score Breakdown

81vs 55. Market Avg.

All Score 81 / 100 is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.

MRKRMARKET
Value5240
Quality6240
Ownership1517
Growth9145
Dividends-37
check_circle

Marker Therapeutics Inc's Price discount from all time high of 100% is great compared to market average of 41.72%. This indicates MRKR could be a good value stock.

Financial Forecast

AI Price Prediction

line chart placeholder

Analyst Ratings

info
Analyst ratings for this stock instrument are based on analysts' assumptions and should not be solely relied upon for financial decisions.

Correlated Companies

PRICE$755.06
24H (%)arrow_drop_down0.59%
24H ($)-$4.53
MARKET CAP$724.46B
PRICE$439.81
24H (%)arrow_drop_down0.43%
24H ($)-$1.91
MARKET CAP$414.91B
PRICE$147.78
24H (%)arrow_drop_down0.67%
24H ($)-$1.00
MARKET CAP$361.94B
PRICE$126.33
24H (%)arrow_drop_up0.14%
24H ($)$0.18
MARKET CAP$321.01B

About Marker Therapeutics Inc (MRKR)

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma and selected solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia (AML) and acute lymphoblastic leukemia; and off-the-shelf products in various indications. It is also developing MT-401, which is in Phase 2 clinical trial for the treatment of post-transplant AML; MT-401-OTS for the treatment of AML; and MT-601 for the treatment of pancreatic cancer and lymphoma. Marker Therapeutics was founded in 1999 and is headquartered in Houston, Texas.

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Juan F. Vera M.D.
Headquarters
Houston
Employees
67
Exchange
NASDAQ
add Marker Therapeutics Inc to watchlist

Keep an eye on Marker Therapeutics Inc

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
What is Marker Therapeutics Inc's (MRKR) price per share?

The current price per share for Marker Therapeutics Inc (MRKR) is $4.53. The stock has seen a price change of -$0.07 recently, indicating a -1.52% change. This reflects the stock's recent market performance and investor sentiment.

help
What is the 52-week high and low for Marker Therapeutics Inc (MRKR)?

For Marker Therapeutics Inc (MRKR), the 52-week high is $9.68, which is 113.69% from the current price. The 52-week low is $0.76, the current price is 496.05% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help
Is Marker Therapeutics Inc (MRKR) a growth stock?

Marker Therapeutics Inc (MRKR) has shown an average price growth of 162.03% over the past three years. It has received a score of 97 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Marker Therapeutics Inc as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help
What is Marker Therapeutics Inc (MRKR) stock price performance year to date (YTD)?

As of the latest data, Marker Therapeutics Inc (MRKR) has a year-to-date price change of -15.96%. Over the past month, the stock has experienced a price change of 8.11%. Over the last three months, the change has been -6.02%. Over the past six months, the figure is 32.07%.

help
Is Marker Therapeutics Inc (MRKR) a profitable company?

Marker Therapeutics Inc (MRKR) has a net income of -$14.05M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -278.06% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $3.31M, although specific revenue growth data is currently not available. The gross profit is $3.31M. Operating income is noted at -$14.58M. Furthermore, the EBITDA is -$11.79M.

help
What is the market capitalization of Marker Therapeutics Inc (MRKR)?

Marker Therapeutics Inc (MRKR) has a market capitalization of $43.11M. The average daily trading volume is 21.74K, indicating the stock's liquidity and investor engagement.

News

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Approach investments with caution like a driver who slows down on a curvy road.